Hidden Gem: Pharma Stock That Has Entered The US Govt Drug Supply Market

Synopsis: Senores Pharmaceuticals is quietly building a larger global pharma platform with the US at the centre of its growth plan. Backed by a rising ANDA portfolio, acquisitions, manufacturing expansion and entry into America’s federal drug procurement market, the company is trying to move beyond ordinary generics into a more integrated business model.

A small Indian pharma company has started drawing attention after entering a high-barrier part of the US healthcare system. The company is not just selling medicines overseas, but is also building a broader US-focused platform through product approvals, acquisitions, manufacturing capacity, commercialization capabilities and a new route into federal drug procurement.

Senores Pharmaceuticals Limited reported strong growth in FY26, supported by its regulated markets business, rising product launches and expansion across geographies. The company said its total income increased by 62 percent to Rs. 664 crore in FY26, while EBITDA rose 96 percent to Rs. 199.6 crore and PAT jumped 108 percent to Rs. 121.5 crore. Its EBITDA margin improved to 30.1 percent from 24.8 percent in FY25, while PAT margin improved to 18.3 percent from 14.2 percent.

What’s the Big US Story?

The biggest trigger in Senores’ recent updates is its entry into the US federal market through a strategic joint venture called Amerisyn. The company said it entered into a 70 percent joint venture in the US, creating a direct pathway to supply pharmaceuticals to federal, veterans and defense sectors. This opens access to a high-entry-barrier market and is expected to support future growth by using the company’s manufacturing and product capabilities globally.

This is important because the US government drug supply market is not an easy space to enter. It involves procurement systems, long-term contracts, specialized credentials and relationships with federal agencies. In the Q4FY26 earnings call, management said Amerisyn allows Senores to enter US government procurement markets and position its portfolio for the US federal government, Veterans Affairs and military programs. The company also said its partners bring expertise in government procurement and will help it pursue long-term national contracts and FSS tenders.

However, the government supply opportunity should not be seen in isolation. The larger story is that Senores is trying to build a full US ecosystem. This includes approved products, manufacturing facilities, commercialization capabilities and now federal market access. Management itself said these initiatives are aimed at strengthening and solidifying its US operations, which are most strategic to the company.

Building a Product Engine Through ANDAs

For a generic pharma company, ANDAs are the foundation of the US business. In simple terms, an ANDA is the approval required to sell a generic drug in the US market. Senores has been scaling this portfolio aggressively. As of March 2026, the company had 51 approved ANDAs covering more than 150 product strengths. Over the previous year, its approved ANDA portfolio more than doubled from 22 ANDAs in March 2025 to 51 ANDAs in March 2026.

The company has not launched all these products yet, which is where the growth visibility comes from. Out of the approved portfolio, 20 ANDAs had already been commercially launched, while another 30 approved ANDAs covering over 100 strengths were planned to be launched over the next few quarters. Apart from this, Senores has about 27 molecules involving more than 60 strengths under different stages of development.

The Q4FY26 data also shows how quickly the pipeline has expanded. Approved ANDAs increased from 26 in Q4FY25 to 51 in Q4FY26, while corresponding ANDA products increased from 61 to 151. The company also said 30 ANDAs with 105 corresponding products are yet to be launched, with a target share of more than USD 630 million on a gross basis.

From Products to Manufacturing Control

Senores is not only building a product pipeline; it is also adding manufacturing strength. The acquisition of Apnar Pharmaceuticals is a key part of this strategy. In Q4FY26, the company acquired a 75 percent stake in Apnar, with the remaining 25 percent expected to be completed later. Management said Apnar’s USFDA-approved manufacturing facility gives Senores strategic advantages and creates a strong platform for long-term growth.

The facility is relatively new, has multiple pre-constructed clean rooms and is expansion-ready. Because it is India-based, management said it can support cost efficiency, while the diversified manufacturing footprint can improve scalability, speed up product commercialization and help the company pursue more CDMO and CMO opportunities. The facility is also approved by UK MHRA and Health Canada, giving Senores additional access beyond the US.

The Apnar acquisition also added approved products. In the Q3FY26 earnings call, management said the acquisition included five approved ANDAs, which were expected to generate at least USD 16 million to USD 18 million in revenue over the next 12 to 15 months. Management also said the facility would allow select products to be shifted from the US to India where US-based manufacturing is optional, improving flexibility and cost advantages.

Zoraya Adds the Commercialization Layer

The next layer in Senores’ US strategy is commercialization. In Q3FY26, the company set up Zoraya Pharmaceuticals to strengthen its US operations. Management said Zoraya is equipped to manage the full lifecycle of pharmaceutical commercialization and will focus on direct distribution and marketing of some strategic products in the US.

This matters because manufacturing a product and successfully selling it in the US are two different things. A company needs distribution, market access, pricing strategy and customer relationships. Senores’ move into Zoraya suggests that it wants more control over the value chain instead of depending only on external partners.

Senores entered into an agreement to acquire a 51 percent membership interest in Zoraya Pharmaceuticals, LLC, a US-based entity. Zoraya is being established to strengthen vertical integration and commercialize the acquired ANDA portfolio under a dedicated market-facing brand.

CDMO, CMO and Emerging Markets Add Scale

Alongside its owned products, Senores is also building a CDMO and CMO business. This means it manufactures or develops products for other companies. Management said the key differentiator here is its ability to offer end-to-end solutions, covering development, scale-up, exhibit batch manufacturing, supply chain planning, commercial production and regulatory support.

This business also supports operating leverage. Management said the CMO business helps absorb a significant portion of operating cost and drives large-scale volumes. In Q4FY26, the company said its CDMO and CMO business focuses on specialty, government supplies and controlled substances, and that it is positioned in the US and India to provide end-to-end solutions from development to commercialization.

Emerging markets are another part of the company’s growth strategy. The data shows that the emerging markets portfolio had 478 approved products and 904 pipeline products by Q4FY26 across more than 40 countries. Management also said the business is shifting toward niche molecules and improved go-to-market strategies, helping better pricing and margins.

Financial Performance and the Road Ahead

Senores’ FY26 performance shows that the strategy has already started reflecting in numbers. In FY26, regulated markets revenue stood at Rs. 427.4 crore, growing 74.6 percent year-on-year, and contributed 64 percent of total revenue. Emerging markets revenue stood at Rs. 145 crore, growing 19.7 percent, while branded generics revenue grew 385.3 percent to Rs. 40 crore.

The company also improved cash flow. By Q4FY26 cash flow from operations stood at Rs. 75 crore in FY26, showing significant improvement over the previous year. Management also highlighted that EBITDA-to-operating cash flow conversion improved.

Looking ahead, management has guided for revenue growth of approximately 30 percent to 40 percent in FY27 and PAT growth of about 50 percent to 60 percent. This confidence is based on its order pipeline and clear visibility on upcoming product launches.

The Bigger Picture

Senores is still not a low-risk story. The US generic market is highly competitive, product launches need execution, acquisitions need integration and regulatory compliance remains critical. The company is also doing many things at the same time, from ANDA launches and acquisitions to CDMO scale-up, emerging market expansion and federal procurement entry.

But the strategy is clear. Senores is trying to move from being a small generic pharma player to a more integrated US-focused specialty generics platform. Its business is being built around products, manufacturing, commercialization and market access.

The key question is whether Senores can convert this pipeline and infrastructure into durable revenue and cash flows over the next few years. If execution remains strong, the company’s US strategy could become a major growth driver. But if launches are delayed, pricing weakens or integration becomes difficult, the risks could also show up quickly.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Hidden Gem: Pharma Stock That Has Entered The US Govt Drug Supply Market appeared first on Trade Brains.